Status:
UNKNOWN
Use of Desferal for Prevention of ARDS in Hospitalised Cases Documented With Covid 19 Infection
Lead Sponsor:
Hesham Al-Inany
Conditions:
Covid 19
Eligibility:
All Genders
Phase:
PHASE4
Brief Summary
To evaluate the efficacy of using Desferal injections for prevention of ARDS in moderate cases with fever , chest tightness and relevant chest images
Detailed Description
COVID-19 is a condition caused by a coronavirus (called SARS-CoV-2) that was first identified in late 2019. In 2020, the virus has spread to many countries around the world and neither a vaccine again...
Eligibility Criteria
Inclusion
- Patients positive for Covid 19 admitted to hospital with chest tightness
Exclusion
- Pregnancy
- Breastfeeding
- Known severe hepatic impairment
- Known severe renal impairment
- Known porphyrias
- Diabetes mellitus
- Known G6PD deficiency
- Known myasthenia gravis
- Known severe psoriasis
- Known severe neurological disorders (especially those with a history of epilepsy - may lower seizure threshold)
Key Trial Info
Start Date :
June 1 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2020
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT04389801
Start Date
June 1 2020
End Date
December 31 2020
Last Update
May 15 2020
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.